Clinical Trial Update: Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 dose-range study evaluating BF2.649 versus placebo in Parkinson's disease patients with excessive daytime sleepiness has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Sleepiness
• Parkinson Disease

Drugs mentioned

• BF2.649 (BF2.649)

Snippet

Sponsor: Bioprojet | Conditions: Excessive Daytime Sleepiness, Parkinson's Disease | Phase 2 | Status: COMPLETED